Characteristics of Recipients of DLI and Outcome of Treatment
| UPN/Age (yr) . | Reason for DLI . | No. of CD3 Cells/kg/d Infused . | Outcome . | GVHD (Y/N) . | Primary Malignancy . | Relapse of Primary Malignancy (Y/N) . |
|---|---|---|---|---|---|---|
| 1330/28.6 | EBV-LPD + 120 | 0.57 × 106/+120 | EBV-LPD eradicated | N | CML-CP | Y |
| 1332/48.8 | EBV-LPD, +181 | 0.20 × 106/+190 | EBV-LPD eradicated | Y | NHL | N |
| 1341/19.7 | EBV-LPD, +99 | 1.00 × 106/+103 | EBV-LPD eradicated | N | Ph+ ALL (CR3) | N |
| 1358/23.3 | EBV-LPD, +102 | 0.23 × 106/+104 | EBV-LPD eradicated | N | CML-CP | Y |
| 1596/14 | EBV-LPD, +113 CMV retinitis, +102 | 0.50 × 106/+116 | EBV-LPD eradicated | N | ALL-2nd relapse | Y |
| 1630 | CMV viremia | 0.10 × 106/+110 | Negative CMV shell vial/antigen | N | Aplastic Anemia | N |
| 1725 | CMV viremia/retinitis | 0.10 × 106/+110 | Negative CMV shell vial/antigen | N | Myelofibrosis | N |
| 1351 | Prophylaxis | 0.10 × 106/+157 | N | ALL-3rd CR | N | |
| 1380 | Prophylaxis | 0.10 × 106/+88 | N | CML-Blastic | N | |
| 1395 | Prophylaxis | 0.10 × 106/+49 | Y | CML-Blastic | N | |
| 1421 | Prophylaxis | 0.10 × 106/+76 | Y | Secondary AML | N | |
| 1377 | Prophylaxis | 0.10 × 106/+79 | Y | CML, accelerated | N |
| UPN/Age (yr) . | Reason for DLI . | No. of CD3 Cells/kg/d Infused . | Outcome . | GVHD (Y/N) . | Primary Malignancy . | Relapse of Primary Malignancy (Y/N) . |
|---|---|---|---|---|---|---|
| 1330/28.6 | EBV-LPD + 120 | 0.57 × 106/+120 | EBV-LPD eradicated | N | CML-CP | Y |
| 1332/48.8 | EBV-LPD, +181 | 0.20 × 106/+190 | EBV-LPD eradicated | Y | NHL | N |
| 1341/19.7 | EBV-LPD, +99 | 1.00 × 106/+103 | EBV-LPD eradicated | N | Ph+ ALL (CR3) | N |
| 1358/23.3 | EBV-LPD, +102 | 0.23 × 106/+104 | EBV-LPD eradicated | N | CML-CP | Y |
| 1596/14 | EBV-LPD, +113 CMV retinitis, +102 | 0.50 × 106/+116 | EBV-LPD eradicated | N | ALL-2nd relapse | Y |
| 1630 | CMV viremia | 0.10 × 106/+110 | Negative CMV shell vial/antigen | N | Aplastic Anemia | N |
| 1725 | CMV viremia/retinitis | 0.10 × 106/+110 | Negative CMV shell vial/antigen | N | Myelofibrosis | N |
| 1351 | Prophylaxis | 0.10 × 106/+157 | N | ALL-3rd CR | N | |
| 1380 | Prophylaxis | 0.10 × 106/+88 | N | CML-Blastic | N | |
| 1395 | Prophylaxis | 0.10 × 106/+49 | Y | CML-Blastic | N | |
| 1421 | Prophylaxis | 0.10 × 106/+76 | Y | Secondary AML | N | |
| 1377 | Prophylaxis | 0.10 × 106/+79 | Y | CML, accelerated | N |